Adicet Bio (ACET) “announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,000,000 shares of common stock. Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. Truist Securities is also acting as a joint bookrunner. Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the offering.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Announces Major Stock Offering Agreement
- Adicet Bio Reports Promising Phase 1 Study Results
- Adicet Bio’s ADI-001 shows positive preliminary Phase 1 results in LN and SLE
- Adicet Bio’s Promising CAR γδ T Cell Therapy: A Buy Rating Amidst Anticipated Breakthroughs in Lupus Treatment
- Adicet Bio’s Promising Developments and Strategic Advancements Justify Buy Rating